Kura Oncology, Inc.
Kura Oncology, Inc. (KURA) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · KURA · as of Sep 30, 2025
Ownership Breakdown
208
Institutional Holders
▲ 23 vs Q2
$743.16M
Total Inst. Value
▲ $269.08M vs Q2
88.77M
Shares Outstanding
freeFloat 96.78%
83.96M
13F Shares Held
▲ 1.80M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
KURA largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. pharmaceutical preparations | 9.52M | 10.86% | 10.86% | $84.21B | Nov 12, 2025 | ▲ 44.8K |
BVF INC/IL pharmaceutical preparations | 8.62M | 9.84% | 9.84% | $76.26B | Nov 14, 2025 | ▲ 863.0K |
SUVRETTA CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 8.12M | 9.27% | 9.27% | $71.83B | Nov 14, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 5.47M | 6.24% | 6.24% | $48.40B | Nov 7, 2025 | ▲ 120.2K |
ARMISTICE CAPITAL, LLC pharmaceutical preparations | 4.67M | 5.33% | 5.33% | $41.35B | Nov 17, 2025 | ▼ 1.53M |
STATE STREET CORP pharmaceutical preparations | 3.34M | 3.82% | 3.82% | $29.59B | Nov 14, 2025 | ▲ 306.3K |
PROSIGHT MANAGEMENT, LP pharmaceutical preparations | 2.76M | 3.15% | 3.15% | $24.41B | Nov 14, 2025 | ▼ 422.7K |
GOLDMAN SACHS GROUP INC pharmaceutical preparations | 2.61M | 2.99% | 2.99% | $23.14B | Nov 14, 2025 | ▲ 1.68M |
AQR CAPITAL MANAGEMENT LLC pharmaceutical preparations | 2.24M | 2.56% | 2.56% | $19.84B | Nov 14, 2025 | ▲ 1.30M |
JACOBS LEVY EQUITY MANAGEMENT, INC pharmaceutical preparations | 2.22M | 2.54% | 2.54% | $19.69B | Nov 17, 2025 | ▲ 1.12M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
29
Increased
+10.25M shares5
New Positions
first time holders12
Decreased
−6.63M shares0
Sold Out
fully exitedNet shares change (top 50)
+3.62M
+10.25M / −6.63M
Net new holders
+22
5 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
KURA insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
7
Buy transactions
4
Sell transactions
1.75
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Parks Diane L. director | Jun 4, 2026 | Award | 35,000 | $8.77 | $306.9K | 35.0K | Form 4 ↗ |
VASCONCELLES MICHAEL director | Jun 4, 2026 | Award | 35,000 | $8.77 | $306.9K | 35.0K | Form 4 ↗ |
Hasnain Faheem director | Jun 4, 2026 | Award | 35,000 | $8.77 | $306.9K | 35.0K | Form 4 ↗ |
Collins Helen Louise director | Jun 4, 2026 | Award | 35,000 | $8.77 | $306.9K | 35.0K | Form 4 ↗ |
SCHAFER CAROL director | Jun 4, 2026 | Award | 35,000 | $8.77 | $306.9K | 35.0K | Form 4 ↗ |
Szela Mary T director | Jun 4, 2026 | Award | 35,000 | $8.77 | $306.9K | 35.0K | Form 4 ↗ |
Malley Thomas director | Jun 4, 2026 | Award | 35,000 | $8.77 | $306.9K | 35.0K | Form 4 ↗ |
Powl Brian T. Chief Commercial Officer | May 21, 2026 | Sale | 10,000 | $11.00 | $110.0K | 173.6K | Form 4 ↗ |
Powl Brian T. Chief Commercial Officer | May 19, 2026 | Sale | 339 | $9.21 | $3.1K | 183.6K | Form 4 ↗ |
FORD KATHLEEN Chief Operating Officer | May 19, 2026 | Sale | 2,257 | $9.08 | $20.5K | 153.6K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Kura Oncology, Inc. (KURA) is primarily owned by institutional investors, who hold approximately 94.6% of total shares outstanding. Company insiders own approximately 3.22%, while retail and public investors account for the remaining 2.20%.
The largest institutional shareholder of Kura Oncology, Inc. is BLACKROCK, INC., holding approximately 9.52 million shares — equal to 10.86% of outstanding shares — as of September 30, 2025.
A total of 208 institutional investors currently hold KURA stock, with a combined institutional value of approximately $743,163,608 as of the most recent 13F filing period.
Frequently asked questions
KURA ownershipKura Oncology, Inc. (KURA) is primarily owned by institutional investors, who hold approximately 94.6% of shares. The largest shareholder is BLACKROCK, INC. with a 10.86% stake. Company insiders hold 3.22%. Data sourced from SEC Form 13F as of September 30, 2025.